Health-care shares were flat to higher in pre-market trading Monday.
Roka Bioscience ( ROKA ), a molecular-diagnostics company, said its Q2 loss shrank as revenue more than doubled. Roka reported its Q2 net loss narrowed to $7.4 million, or a loss of $11.28 per share, from $7.9 million, or a loss of $15.96 per share, in the same period last year. ROKA shares were steady at $10.49 pre-market.
Repligen ( RGEN ), which develops consumable products for biological drugs, Q2 results above analysts' expectations and raised its revenue guidance for the year. RGEN was up more than 4% pre-market. Repligen's net income declined to $2.8 million, or $0.09 per share, from $4.5 million, or $0.14 per share, a year earlier. Two analysts surveyed by Capital IQ had predicted a profit of $0.06 per share, on average.
Alliqua ( ALQA ), a biomedical company, reported narrower-than-estimated loss in Q2 as revenue more than doubled. Its Q2 net loss expanded to $6 million, or $0.39 loss per diluted share, in the April-to-June period, from $2.1 million, or $0.33 loss per diluted share, a year earlier.
Molina Healthcare ( MOH ) announced late Friday its Molina Healthcare of Florida subsidiary signed an agreement with First Coast Advantage to acquire certain assets tied to First Coast Advantages' Medicaid business. Financial terms of the deal weren't disclosed. MOH trades in a 52-week range of $31.10 to $47.22, with shares steady at $40.63 pre-market.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.